Home > Insider Trading > Filing (0001062993-23-020933)

Filing Details

Accession Number:: 0001062993-23-020933
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-11-15 18:54:20
Reporting Period:: 2023-11-13

Accepted Time:: 2023-11-15 18:54:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1885522	Neumora Therapeutics Inc.	NMRA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219039	Keith Crandell	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219042	Robert Nelsen	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1229592	Steven Gillis	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1906837	Arch Venture Fund Xii, L.p.	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1979548	Arch Venture Partners Xii, Llc	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1979765	Arch Venture Partners Xii, L.p.	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-11-13	31,653	$11.75	4,127,850	No	4	P	Indirect	By ARCH Venture Fund XII, L.P.
Common Stock	Acquisiton	2023-11-14	3,357	$11.98	4,131,207	No	4	P	Indirect	By ARCH Venture Fund XII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By ARCH Venture Fund XII, L.P.
No	4	P	Indirect	By ARCH Venture Fund XII, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive.
Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.